What We Offer
The HTCS Facility can accommodate assays based on both molecular tar gets (enzymes, receptors, protein-protein interactions, etc) and functional cell-based assays.
The HTCS Facility supports two fully automated liquid handling systems and three types of plate reader, enabl ing high capacity assays to be formatted using a wide range of technologies (fluorescence, luminescence, colourimetric and radiometr ic) and the screens to be run at a throughput of up to 100,000 assay points per day.
The range of assay technologies supported for formatting molecular screens includes, AlphaScreen™, time resolved fluorescence (DELPHIA™, and LANCE™), fluorescence polarisation, steady-state fluorescence, photometry, chemilu minescence, ELISA, scintillation proximity and filtration-based separations.
For cell-based screens, supported assays include reporter genes (luciferase, green/yellow fluorescent protein s, alkaline phosphatase, beta-galactosidase), BRET™ (protein-protein interactions) or assays measuring biochemical responses s uch as cell-surface antigen expression, cytokine expression, cell proliferation and cytotoxicity. The HTCS Facility has recently in vested in automated high content screening instrumentation to enable more dynamic cell-based assay capabilities.
In line with current international best practice, The HTCS Facility has an “open access” intellec tual property policy. It will not retain intellectual property rights (either ownership or beneficial) of compounds discovered, dev eloped and commercialised by client organizations unless otherwise negotiated on collaborative terms.
BD Biosciences Pathway HT high content screening imaging system